A privately-owned rare disease biotech preparing for a global Phase 3 clinical trial faced significant contract challenges with its CRO. Misaligned terms created limited leverage to enforce performance, slow responsiveness to operational issues, and exposure to budget overruns. Seuss+ was engaged to renegotiate contracts, protect the sponsor’s position, and establish governance structures to hold the CRO accountable.
Driving Clinical Trial Success in CNS – Pivotal Phase 3 Study
A privately-owned clinical-stage biotechnology company, focused on developing therapies for CNS indications, faced the high-stakes challenge of running a pivotal Phase 3 clinical trial for its lead asset. Partnering with a small CRO experienced in the disease area but inexperienced in complex global trials posed significant risks to operational delivery and future asset value. Seuss+ was engaged to optimize vendor alignment, governance, and inspection readiness to ensure trial success.
Overcoming Patient Recruitment Challenges in a Pivotal Rare Disease Study
A privately-owned biotechnology company, backed by over £270M in private financing, was running a complex global Phase 3 rare disease study with strict inclusion criteria. Nearly a year into recruitment, only 45 of 150 sites were activated and just 7 of 225 patients enrolled. With increasing board concerns over trial feasibility, Seuss+ was brought in to stabilize recruitment and restore confidence in the study’s success.
Driving Clinical Trial Success in Rare Diseases A Global Phase 3 Study
A privately-owned biotechnology company, backed by leading life science investors and over £270M in private financing, faced significant challenges running a global Phase 3 rare disease trial with a large CRO. With slow site activation, recruitment delays, and increasing board concerns over study feasibility, the sponsor engaged Seuss+ to restore confidence, accelerate timelines, and protect budget integrity.
Fully-Integrated Vendor Management Support in Phase 2
A high-potential biotech, entering Phase 2 with an ambitious formulation study, faced late-stage strategic changes that rendered its original CRO unsuitable. Operating with a lean team and under competitive pressures, the sponsor required rapid CRO transition, complete vendor oversight, and embedded operational expertise to stay on schedule and protect data integrity.
We can help you